secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001104659-22-036307
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics appoints Alfred Sandrock as President and CEO, effective March 22, 2022
--------------------------------------------------------------------------------

- Alfred Sandrock, former Biogen EVP of R&D, appointed President and CEO effective March 22, 2022.
- Sandrock receives base salary of $600,000, signing bonus of $50,000, target annual bonus of 55% of base salary.
- Equity grants: stock option for 940,600 shares and RSU for 100,000 shares, both vesting over four years.
- Michael Higgins ceases as Interim CEO, remains Chairman and independent director; receives $30,000 transition retainer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922036307/0001104659-22-036307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922036307/tm229951d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-036307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer